Latest studies
- Active not recruitingPHASE3
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
This study looks at a new drug, Monalizumab, combined with Cetuximab, for people with head and neck cancer that has come back or spread. It compares this combination to Cetuximab with a dummy drug (placebo) to see if it's safe and effective.
Squamous Cell Carcinoma of the Head and NeckBrazil - RecruitingPHASE2, PHASE3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
This study is looking at a new medicine, RO7771950, for HER2-positive breast cancer that has spread or is hard to remove. It compares RO7771950 with an existing medicine, tucatinib, both given with trastuzumab and capecitabine. The aim is to see if the new medicine works well and is safe.
HER2-positive Breast CancerBrazil - Active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMetastatic Non-small Cell Lung CancerBrazil - Active not recruitingPHASE3
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
This study is looking at a new medicine called Olezarsen for people with very high triglyceride levels. It's an ongoing study for those who have already started the treatment in previous trials, checking its long-term safety and how well it's tolerated.
Severe HypertriglyceridemiaBrazil - RecruitingPHASE3
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.
CLLChronic Lymphocytic LeukemiaBrazil - Active not recruitingNA
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
This study looks at a new device for people with heart failure. It wants to see if the Edwards APTURE shunt system can help improve symptoms for those whose hearts pump well but still feel unwell, even with their usual medicines.
Heart FailureBrazil - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
Endometrial CancerBrazil - RecruitingNA
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
This study looks at a new way to lower ovarian cancer risk in women with certain gene changes. Instead of removing both ovaries and fallopian tubes at once, it explores removing only the fallopian tubes first, and the ovaries later, to delay menopause and its effects. We want to see if this new approach is safe and effective.
BRCA1 Gene MutationBRCA2 Gene MutationRAD51C Gene MutationRAD51D Gene MutationBrazil - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
This study looks at a new drug, claseprubart, for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see if the drug helps people with CIDP and if it's safe. Some participants will receive the drug, and others a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyBrazil - RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for adults aged 40-80 with COPD that's not well-controlled. We want to see if it helps improve breathing, is safe, and has manageable side effects compared to a dummy medicine.
Chronic Obstructive Pulmonary DiseaseBrazil - RecruitingPHASE4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
This study looks at whether blood-thinning medicines (anticoagulants) can prevent strokes and other heart-related problems in people who have had temporary episodes of an irregular heartbeat called atrial fibrillation (AF) during stressful times like surgery or serious illness.
StrokeAtrial FibrillationBrazil - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaBrazil - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaBrazil - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
This study looks at a new drug called anifrolumab for adults with muscle conditions like polymyositis or dermatomyositis. Researchers want to see if it's safe and helps improve symptoms when added to their usual treatment.
Polymyositis, DermatomyositisBrazil - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
Muscle Invasive Bladder CancerBrazil - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
This study is looking at a new medicine called KarXT + KarX-EC to see if it can help improve memory and thinking skills in people with Alzheimer's disease. It also checks if the medicine is safe to use. Some people will get the active medicine, others a dummy pill.
Alzheimer's DiseaseBrazil - RecruitingPHASE3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
This study looks at the long-term safety of a new medicine, ianalumab, for people with lupus. It's for those who have already been in an earlier ianalumab study and continues to check how safe and well the medicine is tolerated over time.
Systemic Lupus ErythematosusBrazil - Active not recruitingPHASE3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
This study compares a new drug, SB27, with an existing one, Keytruda, for advanced lung cancer. Both are given with chemotherapy. Researchers want to see if SB27 works as well as Keytruda for patients with non-small cell lung cancer that has spread.
Non-small Cell Lung Cancer Stage IVBrazil - RecruitingPHASE3
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
This study is testing a new eye treatment, EYP-1901, against an existing one, Aflibercept, for people with diabetic macular edema (DME). It aims to see if the new treatment works just as well to improve or keep vision stable.
Diabetic Macular EdemaDMEDiabetic Macular Edema (DME)Brazil - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
Metastatic Breast CancerBrazil - Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
This study looks at how the quality of CPR given to children during a cardiac arrest affects their recovery. Researchers are observing children in hospitals to see if better CPR techniques and after-care improve survival and brain function.
Cardiac ArrestCardiopulmonary ArrestBrazil - Active not recruitingPHASE1, PHASE2
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
This study is testing a new medicine called sotorasib for people with specific advanced cancers carrying a KRAS p.G12C gene change. Researchers want to see if it's safe, how much to give, and if it helps shrink tumours. It's an early-stage trial looking for better cancer treatments.
KRAS p.G12C Mutant Advanced Solid TumorsBrazil - Active not recruitingPHASE2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
This study is testing a new medicine, volixibat, for people with Primary Sclerosing Cholangitis (PSC) who experience bothersome itching. It aims to see if the medicine can reduce itching and affect how PSC progresses.
Primary Sclerosing CholangitisBrazil - Active not recruitingPHASE1
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
This study, called MTAPESTRY 104, is testing a new drug called Anvumetostat, alone or with other treatments, for advanced lung cancers that have a specific genetic change (MTAP-deletion). It aims to find the safest and most effective dose.
Thoracic TumorsNon-small Cell Lung CancerBrazil - Active not recruitingPHASE4
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
This study looks at how a medicine called emicizumab affects the overall health, activity levels, and joints of people with moderate or severe haemophilia A. It's for those already receiving another treatment and planning to switch to emicizumab.
Severe Hemophilia AModerate Hemophilia ABrazil - RecruitingPHASE3
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
This study is looking at a new medicine called maribavir for children and teenagers who have had an organ or stem cell transplant and have a cytomegalovirus (CMV) infection. We want to check if it's safe, how well it works, and find the best dose.
Cytomegalovirus (CMV)Brazil - Active not recruitingPHASE3
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
This study is looking at a new combination of medicines, belrestotug and dostarlimab, for people with a certain type of lung cancer that hasn't been treated before. It compares this combination to a standard treatment (pembrolizumab) and a dummy drug (placebo).
Lung Cancer, Non-Small CellBrazil - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
Hepatocellular CarcinomaBrazil - Active not recruitingPHASE3
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
This study looks at a new medicine called Luspatercept for adults with a certain type of blood disorder (MDS) who have anaemia but don't yet need blood transfusions. It compares Luspatercept to another common medicine, Epoetin Alfa, to see which is better and safer.
Myelodysplastic SyndromesBrazil - Active not recruitingPHASE3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study looks at a new medicine called CagriSema to see how well it lowers blood sugar and helps with weight loss in people with type 2 diabetes. It's compared to another medicine called tirzepatide. Participants will get one of the medicines by chance.
Diabetes Mellitus, Type 2Brazil - Active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
Hepatocellular CarcinomaBrazil - Not yet recruitingPHASE2
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
This study looks at a new combination treatment for advanced bowel cancer that has spread. It combines a new drug, VVD-133214, with an existing immunotherapy, pembrolizumab. The aim is to see if this combination works better than pembrolizumab alone for certain types of bowel cancer.
Colorectal AdenocarcinomaBrazil - Active not recruitingPHASE2
A Study of Mosliciguat in PH-ILD
This study looks at a new inhaled medicine, mosliciguat, for people with high blood pressure in their lungs caused by lung scarring (PH-ILD). It checks if the medicine is safe and if it helps improve their condition. Participants will be given either the new medicine or a dummy medicine.
Pulmonary HypertensionInterstitial Lung DiseaseLung DiseasesVascular DiseasesBrazil - Active not recruitingPHASE2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
This study is testing a new medicine, Volixibat, for people with Primary Biliary Cholangitis (PBC) who experience bothersome itching. We want to see if Volixibat can reduce itching and if it affects how PBC develops. It's a Phase 2 study, meaning we're still learning about its effects.
Primary Biliary CholangitisPBCBrazil - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
Diffuse Large B-Cell LymphomaBrazil - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
Colon AdenocarcinomaRectal AdenocarcinomaBrazil - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung CancerBrazil - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionBrazil - RecruitingPHASE3
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This study is looking at a new medicine called Elecoglipron for people with certain types of heart failure. It compares Elecoglipron to a dummy medicine (placebo) to see if it helps improve heart health outcomes for adults already taking other heart failure medications, including dapagliflozin.
Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Brazil - RecruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
This study is looking at new treatments for triple-negative breast cancer that remains after surgery. It compares a new drug combination (sacituzumab govitecan-hziy and pembrolizumab) with standard treatments to see if it's more effective and safe for patients.
Triple Negative Breast CancerBrazil - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerBrazil - RecruitingPHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
This study compares a new medicine, Elecoglipron, to an existing one, Semaglutide, for adults with Type 2 Diabetes. It aims to see if the new drug is safe and effective for people whose diabetes isn't well-controlled and who have a higher risk of heart problems.
Type 2 Diabetes MellitusBrazil - RecruitingPHASE3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
This study is looking into a new medication called Elecoglipron for weight management. It's for adults who are overweight or have obesity, with or without Type 2 diabetes, to see if it helps them lose weight safely when combined with diet and exercise.
Weight ManagementBrazil - Active not recruitingPHASE2, PHASE3
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
This study is looking at a new medicine called tividenofusp alfa for children and young adults with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. It compares the new medicine to a standard treatment, idursulfase, to see if it's safe and works well.
Mucopolysaccharidosis IIBrazil - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
This study compares a new medicine, NXT007, with standard Factor VIII treatment for people with haemophilia A. It aims to see if NXT007 is safe and works well to prevent bleeding in adults and teenagers aged 12 and older.
Hemophilia ABrazil - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
Relapsed or Refractory Multiple MyelomaBrazil - Active not recruitingPHASE3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
This study, called ARTEMIS, is testing a new medicine called ziltivekimab for people who have had a heart attack. It aims to see if ziltivekimab can prevent future heart problems compared to a dummy medicine.
Cardiovascular RiskAcute Myocardial Infarction (AMI)Brazil - RecruitingPHASE3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
This study is looking at a new medicine called Teplizumab for people aged 1 to 25 with a recent diagnosis of Stage 3 Type 1 Diabetes. It compares Teplizumab to a dummy medicine to see if it makes managing blood sugar easier and reduces how much insulin they need.
Type 1 Diabetes MellitusBrazil - Active not recruitingPHASE2
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
This study is looking at a new treatment called GTX-102 for Angelman Syndrome. It aims to see if the treatment is safe and if it helps improve the condition in people of different ages and genetic types. Some people will get the treatment, and some won't at first.
Angelman SyndromeBrazil - RecruitingPHASE2, PHASE3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
This study is testing a new medicine, VX-147, for people aged 10-65 with a specific type of kidney disease caused by a gene problem. It will check if the medicine helps, if it's safe, and how the body handles it.
Proteinuric Kidney DiseaseBrazil